Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Galectin Therapeutic (GALT)

Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update GlobeNewswire - Fri Nov 14, 7:00AM CST

NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

GALT : 5.74 (-8.89%)
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting GlobeNewswire - Mon Nov 10, 7:00AM CST

New biomarker analyses from the NAVIGATE trial demonstrated consistent antifibrotic effects of belapectin 2 mg/kg Using established criteria for clinically meaningful worsening, a lower proportion of...

GALT : 5.74 (-8.89%)
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference GlobeNewswire - Mon Oct 20, 7:00AM CDT

NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management...

GALT : 5.74 (-8.89%)
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 GlobeNewswire - Tue Oct 7, 7:00AM CDT

NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal...

GALT : 5.74 (-8.89%)
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GlobeNewswire - Tue Sep 2, 7:00AM CDT

NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management...

GALT : 5.74 (-8.89%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update GlobeNewswire - Thu Aug 14, 7:00AM CDT

NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...

GALT : 5.74 (-8.89%)
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 GlobeNewswire - Wed Jul 9, 7:00AM CDT

GALT : 5.74 (-8.89%)
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going FinancialNewsMedia - Wed Jun 18, 1:30PM CDT

Issued on behalf of Oncolytics Biotech Inc.   Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting...

ONCY : 0.9921 (+1.16%)
GALT : 5.74 (-8.89%)
ONC.TO : 1.42 (+2.16%)
CGON : 43.30 (-3.20%)
CATX : 2.40 (+0.42%)
PRPH : 0.1300 (-7.14%)
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going Newswire.ca - Wed Jun 18, 10:19AM CDT

/CNW/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report...

ONCY : 0.9921 (+1.16%)
GALT : 5.74 (-8.89%)
ONC.TO : 1.42 (+2.16%)
CGON : 43.30 (-3.20%)
CATX : 2.40 (+0.42%)
PRPH : 0.1300 (-7.14%)
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension GlobeNewswire - Tue Jun 10, 7:56AM CDT

GALT : 5.74 (-8.89%)

Barchart Exclusives

Most “Safe” Dividend Stocks Don’t Grow Like This… But These 3 Did Barchart - 49 minutes ago
Three Dividend Kings Wall Street rates “Strong Buy”, supported by strong five-year earnings growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot